Johanna Pachmayr

Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma

K. Rudolph, K. Thedieck, A. Koeberle, 2020, Nature Communications.

Inhibition of Cyclin-dependent Kinase 5 – a Novel Strategy to Improve Sorafenib Response in HCC Therapy

Giorgio, S. Zahler, A. Vollmar, 2018 .

Inhibition of Cyclin‐Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy

S. Zahler, A. Vollmar, T. Lehr, 2018, Hepatology.

PI(18:1/18:1) is a SCD1-derived lipokine that limits stress signaling

M. Kwiatkowski, H. Schlüter, K. Rudolph, 2022, Nature Communications.

Metabolic implication of tigecycline as an efficacious second‐line treatment for sorafenib‐resistant hepatocellular carcinoma

A. Vollmar, H. Zischka, A. Gerbes, 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

The long non-coding RNA H19 - a new player in hepatocellular carcinoma

J. Pachmayr, M. Ardelt, Johanna Pachmayr, 2017, Cell stress.

Understanding the mechanism of action of pyrrolo[3,2-b]quinoxaline-derivatives as kinase inhibitors† †Electronic supplementary information (ESI) available: General procedures for the synthesis, characterization and biological evaluation of all reported compounds can be found in the ESI. See DOI: 10.

L. Cascione, S. Zahler, A. Caflisch, 2020, RSC medicinal chemistry.

Small molecule inhibitors of the mitochondrial ClpXP protease possess cytostatic potential and re-sensitize chemo-resistant cancers

A. Vollmar, I. Jeremias, S. Sieber, 2021, Scientific Reports.